Introduction
Psoriasis is a common, chronic inflammatory disease of the skin and joints that affects 2-4% of the general adult population. 1, 2 Psoriasis is associated with impairments in health-related quality of life, even in mild cases, and is associated with excess all-cause mortality in patients with severe disease. 3, 4 The cause of psoriasis remains unknown; however, its pathogenesis involves a complex interaction between genetics, the immune system, and environmental exposures.
Recent evidence suggests that chronic psoriasis may be associated with other conditions that are caused, in part, by chronic inflammation. 5 For example, helper T-cells type 1 (Th-1) chronic inflammation characteristic of psoriasis is also central to the pathophysiology of other conditions such as insulin resistance, atherosclerosis, and plaque rupture leading to thrombotic events. 6, 7 Patients with psoriasis have increased prevalence of traditional cardiovascular (CV) risk factors such as diabetes, 8 hypertension, 9 metabolic dyslipidaemia, 10 tobacco use, 11 and obesity. Furthermore, even after adjusting for these risk factors, recent epidemiological studies support an independent association between psoriasis and myocardial infarction (MI), coronary artery disease, stroke, diabetes, endothelial cell dysfunction, and atherosclerosis. 12 -15 Despite evidence of increased all-cause mortality 4 in patients with severe psoriasis and accumulating evidence of increased prevalence of CV risk factors, there is a paucity of data examining whether psoriasis is associated with increased mortality due to CV disease (CVD) after adjusting for CV risk factors. The purpose of the present study was to determine if patients with severe psoriasis have an increased risk of CV mortality.
Methods
Study population and data source
The study was conducted and is reported based on recommendations of the STROBE statement. 16 The study population was derived from the General Practice Research Database (GPRD), a medical records database in the UK that was established for epidemiological research in 1987. 17 The GPRD is representative of the UK population in terms of age and sex, as well as geographic distribution. Approximately 5% of the UK is represented in this database, and it contains over 9 million patient records with 40 million person-years of follow-up. Over 99% of patients through the National Health Service are registered through their general practitioner (GP) and the database captures both diagnoses and medications. The GPRD has been shown to capture information on diagnoses and treatments from specialists through the GP's electronic medical record. 18 General practitioners received specific training and incurred penalties in order to ensure high quality data. The data are also audited for completeness and a practice receives an up-to-standard (UTS) designation when at least 95% of relevant prescriptions and diagnoses are captured electronically. This database has also been studied in numerous validation studies, including those of psoriasis and CVD, to demonstrate that it captures these outcomes accurately.
1,12
Time period and age eligibility 
Definition of exposure
We defined severe psoriasis patients as those with a diagnostic code of psoriasis, and history of systemic therapy consistent with severe psoriasis. Systemic therapy included phototherapy, psoralen plus ultraviolet A radiation, methotrexate, azathioprine, cyclosporine, oral retinoids (etretinate, acitretin), hydroxyurea, and mycophenolate mofetil. Of note, during the time period that this study was conducted, biologic therapies were not approved for use for psoriasis in the UK. The unexposed population (controls) was composed of patients with no history of a psoriasis diagnostic code.
Sampling of exposed and unexposed cohorts
All patients with severe psoriasis (as defined above) who were age 18 or older at their index date and had at least 1 day of observation time were included. For patients with severe psoriasis, their index date was the first date on or after the first diagnosis of psoriasis in which the patient received a code for treatment consistent with severe disease. For patients without psoriasis, their index date was the date of a medical record entry which was within 60 days of the psoriasis index date. Up to four unexposed subjects who were age 18 or older at their index date were randomly selected for each psoriasis patient, matched on practice, date of registration in the practice, and psoriasis index date (corresponding to a medical record date of the unexposed patient). The matching on dates occurred as follows: registration: +90 days (if registration date 1980, otherwise +5 years), index date: +60 days. The purpose of matching on practice, registration, and index dates was to ensure that patients with and without psoriasis were evaluated by similar physicians during the same time period to account for potential variations in medical practice and to allow for similar degrees of opportunity for GPs to identify medical conditions in psoriasis and non-psoriasis patients.
Person-time calculation
For severe psoriasis patients, follow-up started at the latest of the date of when the patient could first be defined as having severe psoriasis (e.g. received a treatment code consistent with severe disease), was registered with the practice, or the practice was deemed UTS. For unexposed subjects, follow-up started at the latest date of when the patient was registered in the practice, the index date (matched to the psoriasis index date), and the practice was deemed UTS. For all groups, follow-up ended at the date of death, transfer out of the practice, or end of UTS. 
Outcome of interest

Co-variables of interest
We identified traditional CV risk factors including age, sex, hypertension, diabetes, hyperlipidaemia, and smoking (current, former, never) by the presence of diagnostic codes. Body mass index was directly calculated from available data in the medical record.
Analysis
The sample size was determined by including the maximum eligible number of patients with severe psoriasis based on age criteria. We randomly selected up to four unexposed subjects per patient with psoriasis as additional matching yields minimal increases in statistical power. Data were summarized descriptively. Dichotomous variables were tested with Fisher's exact test. Continuous variables were tested with a t-test if they were normally distributed, or with the Wilcoxon test if the data were not normally distributed. We fit age-and sexadjusted Cox models to determine the overall hazard ratio of CV death in psoriasis patients. 19 When univariate Cox models indicated an association of psoriasis with CV death, we fit additional models with covariates included (described above) as well as models with age and sex interaction terms, to determine if the relative risk of CV death in psoriasis patients was different based on sex or age characteristics. The primary model includes major CV risk factors. Body mass index was recorded in about 69% of patients. Each dichotomous variable in the model was checked for proportionality while adjusting for the other covariates in the model by examining diagnostic log -log plots. We used the Greenland method of external adjustment to determine the degree to which our findings could be explained by an unknown or unmeasured confounder. 20 Multiple sensitivity analyses were performed to test the underlying assumptions of our primary analysis. All analyses were performed using STATA 10.0, and a Cardiovascular mortality in psoriasis P-value of ,0.05 was threshold for statistical significance, and P , 0.10 for interaction analysis. 
Protection of human subjects
Results
In this study, we identified 3603 patients with severe psoriasis, and 14 330 matched unexposed patients ( Table 1) . Patients with severe psoriasis patients were slightly older and more likely to be male and have established CV risk factors than patients without psoriasis including hypertension, hyperlipidaemia, tobacco use, Type 2 diabetes (P , 0.05 for all). Furthermore, the majority of patients with severe psoriasis were treated with methotrexate ( Table 2 ).
The incidence of mortality due to CVD in unexposed subjects and psoriasis subjects is shown in Table 3 . The frequency of deaths due to CVD was higher in patients with severe psoriasis. The unadjusted overall risk of mortality due to CVD per 1000 person-years was significantly increased (P ¼ 0.002) in patients with severe psoriasis patients (8.75, 95% CI 7.18-10.56) compared with unexposed patients (6.19, 95% CI 5.51-6.93). After adjusting for traditional CV risk factors (age, sex, hyperlipidaemia, hypertension, smoking, diabetes), severe psoriasis was an independent risk factor for death due to CVD (HR 1.57; 95% CI 1.26, 1.96) ( Table 4) . On the basis of these analyses, we estimate that each year there is approximately one excess death from CVD per 283 severe psoriasis patients. There was no statistical interaction (also known as effect modification) between psoriasis and sex (P ¼ 0.99); however, there was an interaction between psoriasis and age (P ¼ 0.07). For example, the adjusted relative risk of CV mortality in a severe psoriasis patient who is 40 years old and 60 years old was 2.69 (1.45, 4.99) and 1.92 (1.41, 2.62), respectively. The adjusted excess risk of CV mortality in a 40-and 60-year-old psoriasis patient was 6.05 deaths/10 000 person-years and 41.30 deaths/10 000 person-years, respectively.
The results were robust to a variety of sensitivity analyses shown in as its inclusion did not alter the association between psoriasis and CV death and it was captured in only 69% of patients (Table 5) . Finally, analysing our data using an external adjustment approach suggests that such an unknown or unmeasured confounder would have to be common in the general population (prevalence of 20%), and have a strong association with psoriasis (OR 2.67 or greater) and a very strong association (OR 6.5 or greater) with CV death in order to render our findings null. 20 
Discussion
The results of this study demonstrate that patients with severe psoriasis have a clinically significant 57% increased risk of CV death beyond the risk of death associated with traditional CV risk factors. On the basis of our data, a patient with severe psoriasis has an excess risk of CV death attributable to psoriasis of 1 in 283 patients per year. The risk of CV mortality in patients with severe psoriasis was not explained by major cardiac risk factors identified in routine medical practice, suggesting that severe psoriasis may be an independent risk factor for CV death. Moreover, the relative risk of CV death associated with severe psoriasis was highest in younger individuals suggesting a process of accelerated CVD in younger severe psoriasis patients. Therefore, it is of utmost importance that patients with severe psoriasis and their providers are aware of this increased risk and that these patients undergo appropriate risk assessment and implementation of prevention strategies.
The strengths of the current study include the utilization of a large population-based database that is well accepted for CV epidemiological studies and well-validated for psoriasis. 1, 9, 17, 18 In addition, the increased risk of CV death and point estimates were robust to a variety of sensitivity analyses ( Table 5) . We attempted to ensure that we were capturing patients who were seen regularly, minimizing the risk that information bias could explain the findings. In addition, even when patients with highest risk for CV death (i.e. those with history of MI, stroke or transient ischaemic attack, or atherosclerotic disease) were excluded, there was still a 56% increase in CV death associated with severe psoriasis. The results also persisted when examining the risk based on different treatments that theoretically could increase (e.g. Two-to-one matching using original controls.
of CVD. 21, 22 Thus, these findings suggest that the increased CV mortality is not due to treatment effect. The results also persisted when restricting the severe group to patients treated with therapy specific to severe psoriasis (e.g. oral retinoids), and when excluding patients with psoriatic arthritis suggesting that the findings are associated with severe skin psoriasis as opposed to misclassification with other diseases in which our systemic therapies may be indicated. Our data are consistent with recent studies that demonstrate that psoriasis is an independent risk factor for coronary artery disease, 12 -15 stroke, 15, 23 and MI. 12, 15 Our study builds upon previous findings that severe psoriasis patients have an increased relative risk CV mortality that is highest in younger individuals by evaluating outpatients, as opposed to hospitalized patients while also controlling for major CV risk factors. 24 Psoriasis is a prototypical Th-1, 17 inflammatory disease, and Th-1 cellular secreted factors (e.g. intracellular adhesion molecule-1, TNF-a) are indeed involved in the pathogenesis of atherosclerosis and MI. 25 Furthermore, given the accumulating evidence of inflammation playing a key role in development, progression, and complications of atherosclerosis, 26 our findings have biological plausibility. Another Th-1 disease, rheumatoid arthritis, has also been shown to be associated with increased risk of MI 27 and multi-vessel coronary disease. 28 Recent studies have shown coronary microvascular dysfunction in patients who have chronic inflammation such as in rheumatoid arthritis or systemic lupus erythematosus. 29 Patients with psoriasis have elevated high-sensitivity C-reactive protein 30 which has been independently associated as a marker for increased risk of CV events. 31, 32 Finally, a recent study showed increased CVD defined as coronary artery disease, peripheral arterial disease, and stroke in patients with psoriasis, 15 however this was not population-based and did not evaluate for CV mortality. In addition to the inflammatory burden driving CAD risk in these disease states, there may be shared genetic risk which contributes as well. Genetics have been shown to play a key role in susceptibility to psoriasis 33 and metabolic disorders, such as diabetes 34 and dyslipidaemia, 35 as well as coronary artery disease. 36 Interestingly, replicated genetic loci identified in psoriasis such as CDKALI have been shown to be associated with Type 2 diabetes. 37 Diabetes has long been known to be a potent risk factor for MI, 38 and a shared genetic component between diabetes and psoriasis may contribute to our findings. Recent studies have found that psoriasis is an independent risk factor for developing diabetes and therefore, it is possible that metabolic affects of psoriasis may mediate the association of psoriasis and CVD. 9, 39 Furthermore, a gene related to blood cholesterol levels, APOE4 (apolipoprotein E-4), 40 was recently shown to be associated with psoriasis, and this too may be a shared mechanism for increasing coronary risk through lipid pathways. Interestingly, two key inflammatory signalling molecules, TNFAIP3 (tumour necrosis factor inducible protein A20) and its interacting protein TNIP1 41 were discovered using genome-wide association to be strongly associated with psoriasis. Variation in the TNFAIP3 gene in mice 42 and in humans 43 has been shown to increase coronary artery disease.
As with all studies, there are important limitations to consider. In database studies, there remains the possibility for misclassification of CV death. If misclassification of CV death is present, such errors would be expected to be non-differential and therefore would bias our results toward the null. Another potential limitation of our study is that we did not examine patients with exclusively incident (new onset) psoriasis. Ideally, an inception cohort study could be performed. However, in diseases such as psoriasis which may not come to medical attention for many years, it is difficult to validly identify truly incident (new onset) cases in a medical records database setting. Finally, although our study suggests that severe psoriasis is an independent risk factor for CV death, it is possible that incomplete measurement of confounders or unknown confounding factors could explain some of the observed association. For example, we did not control for use of specific medications that may alter CV mortality risk, such as angiotensin converting enzyme inhibitors, HMG-CoA reductase inhibitors (statins), and non-steroidal anti-inflammatory drugs. However, our external adjustment analysis reveals that such unmeasured confounding is unlikely to be driving our results.
This study adds to the growing literature suggesting that patients with severe psoriasis are at increased risk of CVD that is not explained by traditional risk factors. This is the first paper to report increased CV mortality in this group of patients while controlling for major cardiovascular risk factors. In this study, severe psoriasis was at least as potent a risk factor for CV death as other major known risk factors such as smoking, 44 hyperlipidaemia, 45 and hypertension. 46 Our results did not show an increase in CV mortality in the presence of hyperlipidaemia, although the results were not statistically significant and therefore should be interpreted cautiously. Although treatment of hyperlipidaemia has been shown to decrease CVD events and subsequent mortality at 1 year, 47 no study has shown that hyperlipidaemia is an independent risk factor for CV death after controlling for age, diabetes, tobacco use, and hypertension. In further analyses (data not shown), when we limited the outcome to only MI, consistent with the literature, hyperlipidaemia was an independent risk factor for MI. This increase in CVD and mortality is important for clinicians to recognize so that counselling and appropriate screening for CVD and its risk factors in patients with severe psoriasis can be implemented. 48, 49 Future studies are necessary to determine how psoriasis should influence cholesterol treatment targets as outlined by guidelines such as Adult Treatment Panel III, in which clinicians are advised to consider emerging CV risk factors in their treatment decisions. Additionally, future studies are indicated to determine what degree of psoriasis severity translates into clinically significant CV risk, as well as to determine if controlling psoriasis results in reduction of CV risk.
